As a hybrid modality that integrates both metabolic and anatomical features, PET/CT has demonstrated significant potential in predicting NAT response in breast cancer and is mentioned in the most updated guidelines [6, 7]. This evidence concerns the gene BRD2 and breast carcinoma.